Gordon L Amidon

List of Publications by Year
in descending order

148	16,799	34076 52	14736 127
papers	citations	h-index	g-index

157	157	157	11261
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 1995, 12, 413-420.	1.7	4,287
2	Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research, 1998, 15, 11-22.	1.7	893
3	Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharmaceutical Research, 1996, 13, 1838-1845.	1.7	819
4	The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceutical Research, 1997, 14, 1568-1573.	1.7	753
5	Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmaceutics, 2004, 1, 85-96.	2.3	691
6	A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan. Molecular Pharmaceutics, 2006, 3, 631-643.	2.3	493
7	Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 2002, 19, 921-925.	1.7	460
8	A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics, 1999, 186, 119-125.	2.6	401
9	Physiological Parameters for Oral Delivery and in Vitro Testing. Molecular Pharmaceutics, 2010, 7, 1388-1405.	2.3	364
10	Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State. Molecular Pharmaceutics, 2014, 11, 3039-3047.	2.3	360
11	Lessons Learned from Marketed and Investigational Prodrugs. Journal of Medicinal Chemistry, 2004, 47, 2393-2404.	2.9	339
12	Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Advanced Drug Delivery Reviews, 1996, 19, 359-376.	6.6	301
13	5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharmaceutical Research, 1998, 15, 1154-1159.	1.7	274
14	Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharmaceutical Research, 1988, 05, 651-654.	1.7	268
15	The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. European Journal of Pharmaceutical Sciences, 2014, 57, 152-163.	1.9	258
16	Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharmaceutical Research, 1993, 10, 264-270.	1.7	221
17	Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2000, 2, 48-58.	1.3	209
18	The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 529-544.	0.6	183

#	Article	IF	Citations
19	The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology, 1990, 99, 1275-1282.	0.6	154
20	Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharmaceutical Research, 1991, 08, 979-988.	1.7	154
21	Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharmaceutical Research, 1990, 07, 863-868.	1.7	152
22	The Suitability of an in Situ Perfusion Model for Permeability Determinations:Â Utility for BCS Class I Biowaiver Requests. Molecular Pharmaceutics, 2006, 3, 686-694.	2.3	134
23	Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharmaceutical Research, 1992, 09, 969-978.	1.7	128
24	pH-dependent swelling and solute diffusion characteristics of poly(hydroxyethyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (methacry	1.7	126
25	A pH- and ionic strength-responsive polypeptide hydrogel: Synthesis, characterization, and preliminary protein release studies. , 1999, 47, 595-602.		112
26	Solubilization and dissolution of insoluble weak acid, ketoprofen: Effects of pH combined with surfactant. European Journal of Pharmaceutical Sciences, 2006, 29, 306-314.	1.9	107
27	G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability, Pharm Res 12, 413â€“420, 1995â€”Backstory of BCS. AAPS Journal, 2014, 16, 894-898.	2.2	105
28	High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations. Molecular Pharmaceutics, 2010, 7, 1827-1834.	2.3	94
29	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. Molecular Pharmaceutics, 2017, 14, 4281-4294.	2.3	94
30	Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharmaceutical Research, 2000, 17, 439-444.	1.7	92
31	In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharmaceutics and Drug Disposition, 2012, 33, 366-377.	1.1	85
32	Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharmaceutical Research, 1998, 15, 1382-1386.	1.7	84
33	Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. Pharmaceutical Research, 1989, 06, 66-70.	1.7	83
34	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	2.6	81
35	Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharmaceutical Research, 1988, 05, 645-650.	1.7	80
36	Toward anIn VivoDissolution Methodology: A Comparison of Phosphate and Bicarbonate Buffers. Molecular Pharmaceutics, 2009, 6, 29-39.	2.3	80

#	Article	IF	Citations
37	Mechanistic analysis of solute transport in an in vitro physiological twoâ€phase dissolution apparatus. Biopharmaceutics and Drug Disposition, 2012, 33, 378-402.	1.1	77
38	In Viv o Predictive Dissolution: Transport Analysis of the CO 2 , Bicarbonate In Vivo Buffer System. Journal of Pharmaceutical Sciences, 2014, 103, 3473-3490.	1.6	74
39	In Vitro and in Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. Pharmaceutical Research, 1990, 07, 975-982.	1.7	72
40	Effects of Gravity on Gastric Emptying, Intestinal Transit, and Drug Absorption. Journal of Clinical Pharmacology, 1991, 31, 968-973.	1.0	71
41	Factors that Influence Stability of Recombinant Adenoviral Preparations for Human Gene Therapy. Pharmaceutical Development and Technology, 1998, 3, 373-383.	1.1	67
42	Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharmaceutical Research, 1998, 15, 1348-1355.	1.7	66
43	Evaluation of a Three Compartment In Vitro Gastrointestinal Simulator Dissolution Apparatus to Predict In Vivo Dissolution. Journal of Pharmaceutical Sciences, 2014, 103, 3416-3422.	1.6	65
44	In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. European Journal of Pharmaceutical Sciences, 2015, 76, 203-212.	1.9	64
45	Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test *. Clinical Pharmacology and Therapeutics, 1997, 61, 531-543.	2.3	63
46	In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases. Journal of Pharmaceutical Sciences, 2015, 104, 2894-2904.	1.6	63
47	The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharmaceutical Research, 1990, 07, 808-815.	1.7	61
48	Comparison of the Permeability of Metoprolol and Labetalol in Rat, Mouse, and Caco-2 Cells: Use as a Reference Standard for BCS Classification. Molecular Pharmaceutics, 2013, 10, 958-966.	2.3	59
49	Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond. AAPS Journal, 2008, 10, 373-379.	2.2	55
50	Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport. Pharmaceutical Research, 1990, 07, 1099-1106.	1.7	53
51	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharmaceutical Research, 1997, 14, 1127-1132.	1.7	53
52	In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drugâ€“Drug Interaction Caused by Acid-Reducing Agents. Molecular Pharmaceutics, 2015, 12, 2418-2428.	2.3	53
53	Pharmacokinetics of Alcohol Following Single Low Doses to Fasted and Nonfasted Subjects. Journal of Clinical Pharmacology, 1977, 17, 199-206.	1.0	52
54	Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharmaceutical Research, 1994, 11, 528-535.	1.7	50

#	Article	IF	Citations
55	Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans. Molecular Pharmaceutics, 2017, 14, 2629-2638.	2.3	49
56	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. Pharmaceutics, 2020, 12, 74.	2.0	49
57	Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharmaceutical Research, 1991, 08, 93-96.	1.7	48
58	The Evaluation of InÂVitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media. Journal of Pharmaceutical Sciences, 2016, 105, 2804-2814.	1.6	48
59	In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. Molecular Pharmaceutics, 2017, 14, 4295-4304.	2.3	46
60	Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics. AAPS PharmSci, 2000, 2, 76-97.	1.3	45
61	Structural requirements for the intestinal mucosal-cell peptide transporter: the need for N-terminal alpha-amino group. Pharmaceutical Research, 1991, 08, 593-599.	1.7	44
62	Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharmaceutics and Drug Disposition, 1994, 15, 719-746.	1.1	44
63	Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharmaceutical Research, 1996, 13, 1631-1634.	1.7	44
64	The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS). European Journal of Pharmaceutical Sciences, 2017, 102, 126-139.	1.9	44
65	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 0.784314 rgBT /Overl Journal of Pharmaceutical Sciences, 2018, 115, 258-269.	1.9	43
66	Mechanism of absorption of the dipeptide alpha-methyldopa-phe in intestinal brush-border membrane vesicles. Pharmaceutical Research, 1990, 07, 308-309.	1.7	42
67	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded â€˜21st Century BA/BEâ€™ project. International Journal of Pharmaceutics, 2018, 548, 120-127.	2.6	41
68	The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharmaceutical Research, 1999, 16, 272-280.	1.7	40
69	Nucleoside Ester Prodrug Substrate Specificity of Liver Carboxylesterase. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 572-580.	1.3	40
70	The Combination of GIS and Biphasic to Better Predict InÂVivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene. Journal of Pharmaceutical Sciences, 2018, 107, 307-316.	1.6	40
71	Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharmaceutical Research, 1991, 08, 1500-1504.	1.7	39
72	Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Molecular Pharmaceutics, 2017, 14, 345-358.	2.3	39

#	Article	IF	Citations
73	Prolidase, a Potential Enzyme Target for Melanoma:â€‰ Design of Proline-Containing Dipeptide-like Prodrugs. Molecular Pharmaceutics, 2005, 2, 37-46.	2.3	37
74	Bio-predictive tablet disintegration: Effect of water diffusivity, fluid flow, food composition and test conditions. European Journal of Pharmaceutical Sciences, 2014, 57, 273-279.	1.9	36
75	Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization. Molecular Pharmaceutics, 2016, 13, 1030-1046.	2.3	36
76	Gastrointestinal Motility Variation and Implications for Plasma Level Variation: Oral Drug Products. Molecular Pharmaceutics, 2016, 13, 557-567.	2.3	34
77	Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 8-19.	2.0	34
78	Mass Transport Analysis of Bicarbonate Buffer: Effect of the CO₂â€“H₂CO₃ Hydrationâ€“Dehydration Kinetics in the Fluid Boundary Layer and the Apparent Effective pK_a Controlling Dissolution of Acids and Bases. Molecular Pharmaceutics, 2019, 16, 2626-2635.	2.3	34
79	Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharmaceutical Research, 1992, 09, 1659-1663.	1.7	33
80	Mixture experimental design in the development of a mucoadhesive gel formulation. Pharmaceutical Research, 1991, 08, 1401-1407.	1.7	32
81	Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharmaceutical Research, 1995, 12, 780-786.	1.7	32
82	Development of a Highly Efficient Purification Process for Recombinant Adenoviral Vectors for Oral Gene Delivery. Pharmaceutical Development and Technology, 1998, 3, 365-372.	1.1	32
83	Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. Pharmaceutical Research, 1993, 10, 400-404.	1.7	31
84	An investigation into the mechanical and transport properties of aqueous latex films: a new hypothesis for the film-forming mechanism of aqueous dispersion system. Pharmaceutical Research, 1993, 10, 405-410.	1.7	31
85	The estimation of solubility in binary solvents: application of the reduced 3-suffix solubility equation to ethanol-water mixtures. Pharmaceutical Research, 1988, 05, 193-195.	1.7	30
86	Effect of micronization on the extent of drug absorption from suspensions in humans. Archives of Pharmacal Research, 1995, 18, 427-433.	2.7	27
87	Viscometric study of polyacrylic acid systems as mucoadhesive sustained-release gels. Pharmaceutical Research, 1991, 08, 1408-1412.	1.7	26
88	Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharmaceutical Research, 1991, 08, 298-305.	1.7	26
89	Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications. Pharmaceutical Research, 1993, 10, 271-275.	1.7	26
90	Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole. Molecular Pharmaceutics, 2017, 14, 1181-1189.	2.3	26

#	Article	IF	Citations
91	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	2.0	24
92	The effect of physical aging on the dissolution rate of anionic polyelectrolytes. Pharmaceutical Research, 1990, 07, 648-653.	1.7	23
93	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonateâ€“CO₂ Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. Molecular Pharmaceutics, 2018, 15, 5291-5301.	2.3	23
94	Viscoelasticity of anionic polymers and their mucociliary transport on the frog palate. Pharmaceutical Research, 1993, 10, 411-417.	1.7	22
95	Drug marker absorption in relation to pellet size, gastric motility and viscous meals in humans. Pharmaceutical Research, 1998, 15, 233-238.	1.7	22
96	Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. , 1998, 19, 169-174.		22
97	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. AAPS Journal, 2017, 19, 1682-1690.	2.2	22
98	Description and Simulation of a Multiple Mixing Tank Model To Predict the Effect of Bile SÃ©questrants on Bile Salt Excretion. Journal of Pharmaceutical Sciences, 1993, 82, 311-318.	1.6	21
99	Synthesis and characterization of valyloxy methoxy luciferin for the detection of valacyclovirase and peptide transporter. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4781-4783.	1.0	21
100	Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. Journal of Pharmaceutical Sciences, 2016, 105, 925-934.	1.6	21
101	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	2.3	21
102	Stereoselective systemic disposition of ibuprofen enantiomers in the dog. Pharmaceutical Research, 1991, 08, 1186-1190.	1.7	20
103	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	2.2	19
104	Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel. Molecular Pharmaceutics, 2020, 17, 3870-3884.	2.3	19
105	First-pass Metabolism of Peptide Drugs in Rat Perfused Liver. Journal of Pharmacy and Pharmacology, 2011, 50, 1013-1018.	1.2	18
106	Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. Molecular Pharmaceutics, 2015, 12, 3399-3407.	2.3	18
107	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British Journal of Clinical Pharmacology, 2018, 84, 2231-2241.	1.1	18
108	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	1.9	18

#	Article	IF	Citations
109	The absence of accessible vitronectin receptors in differentiated tissue hinders adenoviral-mediated gene transfer to the intestinal epithelium in vitro. Pharmaceutical Research, 1997, 14, 1216-1222.	1.7	17
110	Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein. AAPS PharmSci, 2001, 3, 9-17.	1.3	17
111	Mechanistic Basis of Cocrystal Dissolution Advantage. Journal of Pharmaceutical Sciences, 2018, 107, 380-389.	1.6	17
112	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122.	2.0	17
113	Equilibrium and kinetic factors influencing bile sequestrant efficacy. Pharmaceutical Research, 1992, 09, 670-676.	1.7	16
114	Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharmaceutical Research, 1998, 15, 1376-1381.	1.7	16
115	Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharmaceutical Research, 1991, 08, 698-705.	1.7	15
116	Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine. Molecules, 2017, 22, 1322.	1.7	15
117	The Effect of Dosage Release Formulations on the Pharmacokinetics of Propranolol Stereoisomers in Humans. Journal of Clinical Pharmacology, 1995, 35, 374-378.	1.0	14
118	Cytomegalovirus Protease Targeted Prodrug Development. Molecular Pharmaceutics, 2013, 10, 1417-1424.	2.3	14
119	Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Molecular Pharmaceutics, 2021, 18, 3326-3341.	2.3	13
120	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	2.3	12
121	Pulse Packet Stochastic Model for Gastric Emptying in the Fasted State: A Physiological Approach. Molecular Pharmaceutics, 2018, 15, 2107-2115.	2.3	11
122	The in vivo predictive dissolution for immediate release dosage of donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic dissolution apparatus. Journal of Drug Delivery Science and Technology, 2020, 56, 100920.	1.4	10
123	Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme. Molecular Pharmaceutics, 2020, 17, 1706-1714.	2.3	9
124	Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling. AAPS Journal, 2022, 24, 17.	2.2	9
125	Biphasic Dissolution as an Exploratory Method during Early Drug Product Development. Pharmaceutics, 2020, 12, 420.	2.0	8
126	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-ColaÂ® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). Pharmaceutics, 2020, 12, 566.	2.0	8

#	Article	IF	Citations
127	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. PLoS ONE, 2020, 15, e0241441.	1.1	8
128	The role of rheological properties in mucociliary transport by frog palate ciliated model. Pharmaceutical Research, 1994, 11, 1785-1791.	1.7	7
129	In Vitro Characterization of the Biomimetic Properties of Poly(dimethylsiloxane) To Simulate Oral Drug Absorption. Molecular Pharmaceutics, 2017, 14, 4661-4674.	2.3	7
130	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS Journal, 2018, 20, 100.	2.2	7
131	A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children. European Journal of Pharmaceutical Sciences, 2020, 152, 105437.	1.9	7
132	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	2.0	7
133	"5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter,". , 1999, 16, 175-175.		6
134	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS Journal, 2020, 22, 3.	2.2	6
135	Propagation Characteristics of Fasting Duodeno-Jejunal Contractions in Healthy Controls Measured by Clustered Closely-spaced Manometric Sensors. Journal of Neurogastroenterology and Motility, 2019, 25, 100-112.	0.8	5
136	In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil. Molecular Pharmaceutics, 2022, 19, 2048-2060.	2.3	5
137	Improved Protease-Targeting and Biopharmaceutical Properties of Novel Prodrugs of Ganciclovir. Molecular Pharmaceutics, 2018, 15, 410-419.	2.3	4
138	Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochemical Pharmacology, 2018, 156, 147-156.	2.0	4
139	Oral product input to the GI tract: GIS an oral product performance technology. Frontiers of Chemical Science and Engineering, 2017, 11, 516-520.	2.3	2
140	Functional expressions of endogenous dipeptide transporter and exogenous proton/peptide cotransporter inXenopus oocytes. Archives of Pharmacal Research, 1995, 18, 12-17.	2.7	1
141	Dissolution studies as surrogate for bioequivalence. European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25, 65-65.	0.6	0
142	Designing Prodrugs for the hPEPT1 Transporter. ACS Symposium Series, 2000, , 46-53.	0.5	0
143	Title is missing!. , 2020, 15, e0241441.		0
144	Title is missing!. , 2020, 15, e0241441.		0

#	Article	IF	Citations
145	Title is missing!. , 2020, 15, e0241441.		0
146	Title is missing!. , 2020, 15, e0241441.		0
147	Title is missing!. , 2020, 15, e0241441.		0
148	Title is missing!. , 2020, 15, e0241441.		0